ImmunoGen, Inc. (IMGN) |
|
15.87 -0.13 (-0.81%)
|
09-29 16:00 |
|
Open: |
16.03 |
Pre. Close: |
16 |
|
High:
|
16.1 |
Low:
|
15.755 |
|
Volume:
|
3,461,741 |
Market Cap:
|
3,951(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:28:19 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 19.19  One year: 22.41 |
| Support: |
Support1: 15.18 Support2: 14.4 |
| Resistance: |
Resistance1: 16.43 Resistance2: 19.19 |
| Pivot: |
15.4  |
| Moving Average: |
MA(5): 15.37 MA(20): 15.46
MA(100): 16.38 MA(250): 9.54 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 66.6 %D(3): 49.2 |
| RSI: |
RSI(14): 53.3 |
| 52-week: |
High: 20.69 Low: 3.6 |
| Average Vol(K): |
3-Month: 4,128 (K) 10-Days: 3,243 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMGN ] has closed below upper band by 25.0%. Bollinger Bands are 56.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
16.11 - 16.19 |
16.19 - 16.25 |
|
Low:
|
15.56 - 15.65 |
15.65 - 15.72 |
|
Close:
|
15.73 - 15.88 |
15.88 - 15.99 |
|
Company Description |
|
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. |
Headline News |
Sat, 30 Sep 2023
ImmunoGen, Inc. (NASDAQ:IMGN) Given Consensus ... - MarketBeat
Fri, 29 Sep 2023
ImmunoGen Announces Inducement Grants Under Nasdaq Listing ... - Business Wire
Thu, 28 Sep 2023
MEMX’s Options Exchange Launches - Traders Magazine
Thu, 28 Sep 2023
Groundbreaking Findings from Phase 3 MIRASOL Trial Elahere ... - Best Stocks
Wed, 27 Sep 2023
SG Americas Securities LLC Decreases Position in ImmunoGen, Inc ... - Defense World
Tue, 19 Sep 2023
Is ImmunoGen, Inc. (IMGN) Stock a Good Value Tuesday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
249 (M) |
| Shares Float |
230 (M) |
|
% Held by Insiders
|
0.3 (%) |
|
% Held by Institutions
|
84.6 (%) |
|
Shares Short
|
19,100 (K) |
|
Shares Short P.Month
|
17,250 (K) |
Stock Financials |
|
EPS
|
-0.73 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.97 |
|
Profit Margin (%)
|
-96.1 |
|
Operating Margin (%)
|
-96.9 |
|
Return on Assets (ttm)
|
-20.2 |
|
Return on Equity (ttm)
|
-49.2 |
|
Qtrly Rev. Growth
|
487.2 |
|
Gross Profit (p.s.)
|
-0.43 |
|
Sales Per Share
|
0.76 |
|
EBITDA (p.s.)
|
-0.74 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-265 (M) |
|
Levered Free Cash Flow
|
-159 (M) |
Stock Valuations |
|
PE Ratio
|
-22.05 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
8.05 |
|
Price to Sales
|
20.84 |
|
Price to Cash Flow
|
-14.92 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
